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ABSTRACT
Genital psoriasis is a variety of autoimmune dermatological disease — psoriasis with relapsing-remitting course, which 
can have an onset in all age groups. It is most often diagnosed at an advanced stage. Genital psoriasis is considered an embar-
rassing condition and is often misjudged as a sexually transmitted disease or allergic reaction due to low social awareness 
of the disease. The manifestations of genital psoriasis may differ from typical genital dermatoses and with symptoms such 
as itch, erythroderma and vaginal discharge may mimic other diseases at an early stage. The diagnosis and treatment of 
genital psoriasis may be difficult and often requires a multidisciplinary approach. The aim of this article is to present the 
literature review of genital psoriasis concentrating on the clinical presentation, treatment and influence on the quality of 
patients’ life and sexual activity disorders.
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INTRODUCTION AND EPIDEMIOLOGY
Psoriasis is a chronic autoimmune disease often associ-
ated with dermatitis and arthritis. The annual occurrence 
of psoriasis in the American population doubled between 
1970 and 2000, although it may result from improved recog-
nition of the disease [1]. There are no objective international 
diagnostic criteria to verify the diagnosis of psoriasis, that is 
based mostly on clinical observation. Relapsing-remitting 
course of psoriasis is another factor limiting adequate diag-
nosis. A European survey revealed that approximately 1% to 
5% of Europeans suffer from psoriasis and 74% of psoriatic 
patients considered their disease as severe [2]. Psoriasis has 
an equal distribution between men and women. Surpris-
ingly, 32% of respondents reported genital psoriasis (GP) [2]. 
This was an unexpected result, because GP has been con-
sidered a rare manifestation of psoriasis and the literature 
data concerning GP are scarce. Such outcome eludes that 
GP is a more common phenomenon than it was previously 
thought. This is probably mainly due to patients’ embarrass-
ment about discussing the intimate genital area, also the 
majority of subjects do not know which specialist to choose 
for the best advice. General practitioners, dermatologists, 
gynaecologists, urologists and paediatricians are the most 
common choice. The cooperation between patients and 
various clinicians is essential for adequate recognition of 
GP and the improvement of their psychophysical state. The 
Dutch research group further investigated the occurrence 
of GP. Among 1926 respondents 45.5% reported concurrent 
genital involvement. Males predominated in this population 
(53.3% vs 38.2%), which was explained by easier inspection 
of male external genitalia compared to females. In most 
patients the age of onset of GP was between 20 and 40 [3].
SYMPTOMS
The genital skin is very sensitive and fragile to mechani-
cal as well as chemical irritants. The most common irritants 
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are: tampons, sanitary pads, tight clothes, shaving, vaginal 
discharge, sweat, semen, urine, faeces, bath cosmetics and 
soap, lubricants, spermicides. The most characteristic symp-
tom of GP is itch of genital skin. While taking patient’s history 
it is relevant to ask in detail about psoriasis in the family, 
sexual activity including recent partners along with other 
skin lesions in other areas. Psoriatic lesions at the genitalia 
present mostly as well-demarcated, brightly erythematous, 
thin plaques without scaling (Fig. 1), which is typical in other 
areas because of maceration [4]. If scales are present, they 
are observed only on more keratinised parts of the genital 
skin [5]. In addition to plaque-type genital psoriasis, the 
genital area may also be involved in pustular psoriasis [6]. In 
female patients vulvar psoriasis is mostly symmetrical and 
can vary from moist greyish plaques or glossy red plaques 
with no scales in the skin folds to silvery, scaling patches 
adjoining to the outer parts of the labia majora [7]. In males 
genital psoriatic lesions may be located on both scrotal and 
penile skin. The glans penis is the area of genital skin that 
is most commonly affected. Typically, GP does not involve 
the entire penis, scrotum, and inguinal folds [8]. Usually, 
in uncircumcised male patients well-defined non-scaling 
plaques are present under the prepuce and on the proximal 
glans, while in circumcised males red lesions are present 
on the glans and corona [9]. Genital psoriasis is considered 
a variety of the flexural (inverse) psoriasis, with the perineal, 
and axillary flexures affected instead of the typical localiza-
tion of plaques [10].
The diagnosis of GP is usually based on clinical exami-
nation. Since psoriatic patients may present to a variety 
of specialists and GP is considered to be an embarrassing 
health condition, it is recommended to always ask about 
any genital complaints and examine the genital area in 
such patients. Dermatitis, candidiasis, squamous cell carci-
noma, plasma-cell balanitis or vulvitis, lichen planus, syphilis, 
scabies and pediculosis pubis are conditions taken into 
consideration during differential diagnosis of genital skin 
changes [11]. GP is not exclusive for adults, it may also be 
seen in younger patients (Fig. 2). There are many similarities 
between adult and paediatric genital dermatoses, however, 
streptococcal vulvovaginitis appears only at prepuberty, 
while candidiasis at postpuberty [12]. According to Fischer, 
the vulvar presentation of psoriasis is more common in 
children than in adults [13]. The need to search for nail pit-
ting, scalp or postauricular erythema and scaling during 
paediatric clinical examination was also emphasized [13]. 
In a Clinical Audit of 130 cases of vulvar disease in children 
the authors reported that psoriasis is one of the most com-
mon dermatoses in prepubertal girls, but it may involve any 
age group including infants (“napkin psoriasis”) [13–14]. 
Vulva itch and rashes are usually the symptoms presented 
to a paediatrician or general practitioner. The possibility of 
sexual abuse should not be omitted, especially when the 
child presents symptoms of a sexually transmitted disease 
or evidence of trauma is seen [14].
QUALITY OF LIFE
Psoriasis, especially the genital manifestation of the 
disease, has a great negative influence on patients’ quality 
of life. The treatment is long-term and is inconvenient for 
patients because of required regularity and strict compli-
ance to medication regimens. Finlay et al. stated that more 
Figure 1. Psoriatic lesions on the female genitalia — well-
demarcated, brightly erythematous, thin plaques without scaling
Figure 2. Genital psoriasis in a prepubertal girl. Vulvar psoriasis is 
symmetrical with glossy red plaques and no scales in the skin folds
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than 80% of psoriatic patients report problems with social 
contacts and interpersonal relations. Personal life is particu-
larly afflicted by genital psoriasis [15]. Psoriasis influences 
not only physical health, but psychosocial and emotional 
as well. Psoriasis deteriorates general wellbeing to a great-
er extent than most chronic diseases such as diabetes or 
cardiovascular disease [10]. Skin lesions, especially in the 
genital area and on the face may lead to severe depression 
and even to suicidal ideation. In Gupta’s study almost 10% 
of subjects reported a wish to be dead while 5.5% presented 
active suicidal ideation [16]. Supporting regular pharma-
cologic therapy with psychotherapy results in much better 
management of psoriasis and reduction of stress. Integrated 
treatment results in significant improvement in clinical se-
verity of psoriasis. Stress is reported as a triggering factor of 
psoriasis by 60% of patients [17]. A study on the quality of 
life and sexual life in 487 patients with GP concluded that: 
 Ū patients with genital lesions report even significantly 
worse quality of life than patients without genital le-
sions; 
 Ū sexual distress and dysfunction are particularly promi-
nent in women;
 Ū sexual distress is especially high when genital skin is 
affected; 
 Ū the attention given to possible sexual problems in the 
psoriasis population by healthcare professionals is per-
ceived as insufficient by patients [18]. 
A recent report confirmed the abovementioned state-
ments and specified that sexual dysfunction and distress are 
prominent in approximately half of women with psoriasis 
[19]. Meeuwis et al. investigated which factors decrease the 
sexual activity of psoriatic patients. The main ones influenc-
ing distress and dysfunction scores were shame and embar-
rassment about physical appearance, lower sexual desire of 
the patient, annoyance of skin scaling and inconvenience 
of topical therapy [18]. The authors also concluded that 
women’s quality of sexual life is more highly influenced by 
stress levels [18]. The course of the disease may vary during 
pregnancy: 55% of the patients reported improvement, 18% 
demonstrated steady course and 24% noticed worsening 
of psoriasis [20]. Remission of psoriasis during pregnancy 
is probably a result of hormonal levels changes such as 
estrogen, progesterone and glucocorticoids. Th2 based im-
mune response might also be important for improvement of 
patients’ condition [21]. The connection between psoriasis 
and pregnancy complications had also been investigated. 
A significant correlation between psoriasis and pregnancy 
complications such as miscarriage, chronic hypertension 
and perinatal complications and preterm delivery had been 
shown [22]. Pregnancy itself may influence self-esteem and 
result in lack of acceptance of changing appearance. Ad-
ditional stress connected with exposure of genital psori-
atic alterations during regular gynaecological examination 
can trigger depression and worsen the symptoms of the 
disease [23]. After delivery 62-87% of women developed 
new lesions in less than 2 months [24]. There is no reported 
correlation between foetus sex or breastfeeding and pso-
riasis exacerbation [25].
TREATMENT
Treatment of the sensitive genital skin is challeng-
ing, because of the unique genital environment (warmth, 
moisture and exposure to friction) [26]. Moreover, a suit-
able choice of remedies is necessary to avoid irritation in 
this area. The issue is further complicated due to paucity 
of evidence-based data on the efficacy and safety of avail-
able treatment options, originating mostly from individual 
case reports and case series [11]. Aside from genital lesions 
coexisting with severe and extensive psoriasis, treatment 
is generally topical. Topical corticosteroids are the most 
commonly recommended therapeutic option in GP. Owing 
to increased penetration of these agents in genital area 
and the resultant side effects, most authors recommend 
long-term use of weak to moderate corticosteroids; howev-
er, these are often not potent enough to induce a response. 
Others advocate short-term or intermittent administration 
of moderate to potent corticosteroids, or their use as an in-
duction therapy followed by maintenance treatment with 
weaker preparations. Any treatment with topical steroids 
in the genital region should be individualized. Universal 
treatment regimens are not available. It is accepted that 
due to possible adverse effects and tachyplaxis the treat-
ment should not last more than 2–4 weeks. Approved ste-
roid preparations include 1%–2.5% hydrocortisone cream 
(class I — mild), 0.1% hydrocortisone butyrate cream (class 
I), fluticasone propionate (class II — moderate), mometa-
sone furoate ointment (class III — potent) [27]. Sticherling 
recommends treatment with moderately potent steroids 
e.g. methylprednisolone aceponate (class I) and mometa-
sone (class III) or alternatively bethametasone (class II/III) 
[28]. In severe and recalcitrant cases clobetasol propio-
nate 0.05% may be applied daily but not longer than for 
2–4 weeks (class IV — very potent). Some authors suggest 
that bethametasone should be used as a first line drug in 
genital lesions. If no significant response is observed within 
7–10 days, it is recommended to increase dosage or po-
tency of topical steroids [27]. Another option are mild topi-
cal tar preparations and topical vitamin D analogues. Since 
these agents may cause irritation of the sensitive genital 
skin, they are usually prescribed in combination with topi-
cal corticosteroids, rather than in monotherapy [29]. Also 
topical treatment with immunomodulators, pimecroli-
mus ointment or tacrolimus cream, was recommended in 
monotherapy or in combination with weak corticosteroids 
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[30–32]. However, it should be remembered that besides 
irritation, the immunomodulating agents may promote 
allergic dermatitis, candidiasis and (re)activation of viral 
infections [11]. In patients with suspected opportunistic 
bacterial or fungal infections topical antibiotics or keto-
conazole/miconazole should be implemented to prevent 
the Koebner effect [11]. Conservative treatment of genital 
psoriasis includes use of mild emollients and avoiding 
exposure to local irritating factors [33]. Phototherapy and 
laser therapy are not recommended in the genital area [34]. 
In sporadic cases, complete remission of genital psoriasis 
was documented after four weeks of treatment with oral 
dapsone (100 mg once a day) [6, 26]. Psoriasis treatment 
in pregnant women is a challenge and both mother’s and 
foetal health should be taken into consideration, when 
choosing a drug regimen. Despite being classified as C cat-
egory by the FDA, mild to moderate topical corticosteroids 
with emollients are the first line treatment in pregnant pa-
tients with psoriasis. In second line treatment UVB is used, 
while cyclosporine and biological therapy with anti-TNF-α 
are recommended as third line [35]. Unfortunately, pa-
tients commonly do not use prescribed drugs adequately, 
and this has a negative impact on treatment results. The 
low compliance was mostly caused by lack of satisfactory 
efficacy, unpleasant cosmetics components, time con-
sumption and side effects [2]. Moreover, adverse reactions 
resulting in lower quality of life, such as methotrexate 
induced sexual disturbances and impotence, were the 
reasons why many psoriatic patients discontinued therapy. 
Genital psoriasis is an embarrassing disease for most pa-
tients, who usually do not know where to find professional 
advice and are ashamed of reporting the ailments. Little 
social awareness often leads to confusing genital psoriasis 
with sexually transmitted diseases. Nevertheless, patients 
believe that insufficient attention is given to their sexual 
problems while seeking medical advice. Before presenting 
to a specialist, especially young patients try to treat geni-
tal psoriasis with domestic remedies and such behaviour 
usually exacerbates symptoms and patients’ condition. 
Genital psoriasis is not only a dermatological problem 
and for that reason consultations with other specialists 
are recommended for better treatment efficacy. General 
practitioners and paediatricians play a significant role in 
the initial recognition of the disease. Furthermore, derma-
tologists, gynaecologists and urologists’ close cooperation 
is required to achieve a satisfactory outcome in genital pso-
riasis treatment. Proper communication with the patient 
together with holistic treatment increases compliance and 
results in greater quality of life improvements. Involving 
a sexologist in the management of genital psoriasis has 
a significant, positive implication on patients’ wellbeing. It 
was shown in the Dutch study of genital psoriasis aware-
ness programme, that a vast majority of patients obtained 
prompt improvement, when treated by a multidisciplinary 
team of specialists [19].
CONCLUSIONS
Genital psoriasis affects both general and sexual quality 
of life, which was demonstrated in various studies. Genital 
lesions influence female sexual life more significantly, but 
both males and females achieved lower scores in quality 
of life questionnaires in comparison to healthy cohorts. To 
improve the efficacy of treatment a multidisciplinary team 
of clinicians should be involved in all stages of diagnosis and 
treatment. Patient’s psychosocial life aspects are of the great 
importance in case of GP. Discussing all aspects of patients’ 
wellbeing leads to earlier diagnosis, adequate treatment 
and better compliance.
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